Literature DB >> 17645417

The type 1 insulin-like growth factor receptor is over-expressed in bladder cancer.

Mark A Rochester1, Nilay Patel, Benjamin W Turney, David R Davies, Ian S Roberts, Jeremy Crew, Andrew Protheroe, Valentine M Macaulay.   

Abstract

OBJECTIVE: To analyse bladder cancer biopsies and investigate the pattern of expression of the type 1 insulin-like growth factor receptor (IGF1R), a receptor tyrosine kinase that mediates tumour cell proliferation, motility and protection from apoptosis.
MATERIALS AND METHODS: Formalin-fixed specimens of bladder cancer (40 whole-mount, 80 cores on a tumour microarray) and normal bladder (15 samples) were stained immunohistochemically for the IGF1R. The IGF1R expression was also measured by quantitative reverse transcription-polymerase chain reaction (Q-RT-PCR) on RNA extracted from fresh frozen bladder cancers (61) and benign bladder (12).
RESULTS: Of the 15 samples of normal bladder, 14 showed negligible (1+) or light (2+) IGF1R immunostaining. By contrast moderate (3+) or heavy (4+) staining for IGF1R was detected in 89 (74%) of the 120 samples of malignant urothelium. Q-RT-PCR showed significantly higher levels of steady-state IGF1R mRNA in tumours (all cases, Ta-T4) than in normal bladder (P < 0.05), indicating up-regulation at the transcriptional level. This difference was particularly evident when comparing normal urothelium with superficial (Ta-T1) or invasive (T2-4) tumours; only the latter showed significant IGF1R over-expression at the RNA level (P < 0.05 vs normal bladder).
CONCLUSION: The IGF1R is up-regulated in bladder cancer compared with non-malignant bladder, and might contribute to a propensity for invasion.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17645417     DOI: 10.1111/j.1464-410X.2007.06931.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  22 in total

1.  Biomedical text summarization to support genetic database curation: using Semantic MEDLINE to create a secondary database of genetic information.

Authors:  T Elizabeth Workman; Marcelo Fiszman; John F Hurdle; Thomas C Rindflesch
Journal:  J Med Libr Assoc       Date:  2010-10

Review 2.  Neoadjuvant chemotherapy for invasive bladder cancer.

Authors:  Guru Sonpavde; Cora N Sternberg
Journal:  Curr Urol Rep       Date:  2012-04       Impact factor: 3.092

Review 3.  Targeting IGF1R pathway in cancer with microRNAs: How close are we?

Authors:  Arathy S Kumar; Suresh K Rayala; Ganesh Venkatraman
Journal:  RNA Biol       Date:  2018-02-01       Impact factor: 4.652

4.  Phase I dose-escalation study of MEDI-573, a bispecific, antiligand monoclonal antibody against IGFI and IGFII, in patients with advanced solid tumors.

Authors:  Paul Haluska; Michael Menefee; Elizabeth R Plimack; Jonathan Rosenberg; Donald Northfelt; Theresa LaVallee; Li Shi; Xiang-Qing Yu; Patricia Burke; Jiaqi Huang; Jaiqi Huang; Jaye Viner; Jennifer McDevitt; Patricia LoRusso
Journal:  Clin Cancer Res       Date:  2014-07-14       Impact factor: 12.531

Review 5.  New treatments for bladder cancer: when will we make progress?

Authors:  Rosa Nadal; Joaquim Bellmunt
Journal:  Curr Treat Options Oncol       Date:  2014-03

6.  The insulin-like growth factor receptor I promotes motility and invasion of bladder cancer cells through Akt- and mitogen-activated protein kinase-dependent activation of paxillin.

Authors:  David Metalli; Francesca Lovat; Farida Tripodi; Marco Genua; Shi-Qiong Xu; Michela Spinelli; Lilia Alberghina; Marco Vanoni; Raffaele Baffa; Leonard G Gomella; Renato V Iozzo; Andrea Morrione
Journal:  Am J Pathol       Date:  2010-04-15       Impact factor: 4.307

7.  miR-143 inhibits bladder cancer cell proliferation and enhances their sensitivity to gemcitabine by repressing IGF-1R signaling.

Authors:  Hengbing Wang; Qi Li; Xiaobing Niu; Gongcheng Wang; Sinian Zheng; Guangbo Fu; Zengjun Wang
Journal:  Oncol Lett       Date:  2016-11-16       Impact factor: 2.967

8.  Novel agents for advanced bladder cancer.

Authors:  Guru Sonpavde; Aymen A Elfiky; Jonathan E Rosenberg
Journal:  Ther Adv Med Oncol       Date:  2009-07       Impact factor: 8.168

9.  Personalized therapy for urothelial cancer: review of the clinical evidence.

Authors:  Elizabeth A Guancial; Dipanjan Chowdhury; Jonathan E Rosenberg
Journal:  Clin Investig (Lond)       Date:  2011-04

10.  Insulin-like growth factor-1 receptor expression in upper tract urothelial carcinoma.

Authors:  Marie-Lisa Eich; Aline C Tregnago; Sheila F Faraj; Doreen N Palsgrove; Kazutoshi Fujita; Stephania M Bezerra; Enrico Munari; Rajni Sharma; Alcides Chaux; George J Netto
Journal:  Virchows Arch       Date:  2018-10-18       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.